CEBP Infection and Cancer: Biology, Therapeutics, and Prevention Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chao, C.
Right arrow Articles by Hashibe, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chao, C.
Right arrow Articles by Hashibe, M.
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 979-987, May 2006
© 2006 American Association for Cancer Research

NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser Polymorphism and the Risk of Lung, Bladder, and Colorectal Cancers: a Meta-analysis

Chun Chao1,2, Zuo-Feng Zhang1, Julien Berthiller2, Paolo Boffetta2 and Mia Hashibe2

1 Department of Epidemiology, University of California at Los Angeles, Los Angeles, California and 2 IARC, Lyon, France

Requests for reprints: Mia Hashibe, Gene-Environment Epidemiology Group, IARC, 150, cours Albert Thomas, 69372 Lyon Cedex 08, France. Fax: 33-4-72-73-83-20. E-mail: hashibe{at}iarc.fr

NAD(P)H:quinone oxidoreductase 1 (NQO1) is a cytosolic enzyme that catalyzes the two-electron reduction of quinoid compounds into hydroquinones, their less toxic form. A sequence variant at position 609 (C -> T) in the NQO1 gene encodes an enzyme with reduced quinone reductase activity in vitro and thus was hypothesized to affect cancer susceptibility. We conducted meta-analyses focusing on three cancer sites (lung, bladder, and colorectum) to summarize the findings from the current literature and to explore sources of heterogeneity.

Results: There is no clear association between the NQO1 Pro187Ser polymorphism and lung cancer risk in the three ethnic groups examined: odds ratio (ORWhite) C/T + T/T versus C/C = 1.04 [95% confidence interval (95% CI), 0.96-1.13], ORAsian = 0.99 (95% CI, 0.72-1.34), and ORBlacks = 0.95 (95% CI, 0.66-1.36). However, a modestly increased risk was suggested for the variant homozygotes in whites (OR T/T versus C/C, 1.19; 95% CI, 0.94-1.50). Analysis excluding one outlier study suggested the variant allele may be associated with reduced lung cancer risk in Asians. Meta-analyses for bladder and colorectal cancer suggested a statistically significant association with the variant genotypes in whites. In stratified analyses, the NQO1 Pro187Ser variant genotypes were associated with slightly increased lung cancer risk in white ever smokers but not in white never smokers and were mainly associated with a reduced risk of lung adenocarcinoma but not squamous cell carcinoma in Asians.

Conclusions: Results from our meta-analyses suggest that the variant NQO1 Pro187Ser genotype may affect individual susceptibility to lung, bladder, and colorectal cancer. Such effects of the NQO1 polymorphism seem to be modified by ethnicity and smoking status. (Cancer Epidemiol Biomarkers Prev 2006;15(5):979–87) (Cancer Epidemiol Biomarkers Prev 2006;15(5):979-986)




This article has been cited by other articles:


Home page
JAMAHome page
L. M. Dong, J. D. Potter, E. White, C. M. Ulrich, L. R. Cardon, and U. Peters
Genetic Susceptibility to Cancer: The Role of Polymorphisms in Candidate Genes
JAMA, May 28, 2008; 299(20): 2423 - 2436.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
J. M. Cunningham, S. J. Hebbring, S. K. McDonnell, M. S. Cicek, G. B. Christensen, L. Wang, S. J. Jacobsen, J. R. Cerhan, M. L. Blute, D. J. Schaid, et al.
Evaluation of Genetic Variations in the Androgen and Estrogen Metabolic Pathways as Risk Factors for Sporadic and Familial Prostate Cancer
Cancer Epidemiol. Biomarkers Prev., May 1, 2007; 16(5): 969 - 978.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
A. Begleiter, D. Hewitt, A. W. Maksymiuk, D. A. Ross, and R. P. Bird
A NAD(P)H:Quinone Oxidoreductase 1 Polymorphism Is a Risk Factor for Human Colon Cancer
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2422 - 2426.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2006 by the American Association for Cancer Research.